Anthropometric data of patients (n = 8 women, n = 8 men)
| Patient . | Sex . | Age (years) . | BMI (kg/m2) . | HbA1c, % (mmol/mol) . | Glucose-lowering drugs at inclusion . | End dose (mg) . | Hypoglycemic events, liraglutide (n) . | ||
|---|---|---|---|---|---|---|---|---|---|
| Liraglutide | Glimepiride | Liraglutide | Glimepiride | ||||||
| 01* | F | 27 | 24.0 | 8.1 (65) | Glimepiride 1.5 mg × 1 | 1.8 | 4.0 | — | — |
| 02 | F | 54 | 26.5 | 6.5 (48) | Tolbutamide 500 + 250 + 250 mg | 1.8 | 2.5 | — | — |
| 03 | M | 27 | 24.3 | 5.4 (36) | Glimepiride 1.5 mg × 1 | 1.8 | 4.0 | — | 1 |
| 04 | M | 38 | 24.4 | 6.5 (48) | Repaglinide 0.5 mg × 2 | 1.8 | 3.0 | — | 1 |
| 05 | M | 24 | 25.1 | 7.0 (53) | No treatment | 1.8 | 1.0 | — | 1 |
| 06† | F | 23 | 25.4 | 4.7 (28) | Glimepiride 0.5 mg × 1 | 1.8 | 1.0 | — | 1 |
| 07‡ | F | 24 | 20.5 | 5.6 (38) | Glimepiride 1.0 mg × 1 | NA | NA | — | — |
| 08 | M | 71 | 26.7 | 6.8 (51) | Gliclazide 30 mg × 1 | 1.8 | 3.0 | — | 1 |
| 09 | F | 25 | 21.3 | 5.4 (36) | Repaglinide 1 mg × 1 | 1.8 | 1.0 | — | 1 |
| 10 | F | 67 | 22.9 | 6.6 (49) | Glimepiride 4.0 mg × 1 | 1.8 | 4.0 | — | — |
| 11† | F | 53 | 26.4 | 6.4 (46) | Glimepiride 1.5 mg × 1 | 1.8 | 3.5 | — | 4 |
| 12 | M | 34 | 27.5 | 7.0 (53) | Glimepiride 1.0 mg × 1 | 1.8 | 3.5 | — | 3 |
| 13 | M | 29 | 26.0 | 5.5 (37) | Glimepiride 1.5 mg × 1 | 1.8 | 1.5 | — | — |
| 14* | F | 56 | 24.5 | 7.9 (63) | Glimepiride 4.0 mg × 1 | 1.8 | 4.0 | — | — |
| 15 | M | 42 | 27.9 | 6.3 (45) | Glimepiride 3.0 mg × 1 | 1.8 | 2.0 | 1 | 3 |
| 16 | M | 28 | 24.4 | 7.3 (56) | Glimepiride 1.0 mg × 1 | 1.8 | 1.0 | — | 2 |
| Mean ± SEM | 39 (range 23–67) | 24.9 ± 0.5 | 6.4 ± 0.2 (47 ± 3) | 1.8 ± 0 | 2.5 ± 0.3 | 1 | 18 | ||
| Patient . | Sex . | Age (years) . | BMI (kg/m2) . | HbA1c, % (mmol/mol) . | Glucose-lowering drugs at inclusion . | End dose (mg) . | Hypoglycemic events, liraglutide (n) . | ||
|---|---|---|---|---|---|---|---|---|---|
| Liraglutide | Glimepiride | Liraglutide | Glimepiride | ||||||
| 01* | F | 27 | 24.0 | 8.1 (65) | Glimepiride 1.5 mg × 1 | 1.8 | 4.0 | — | — |
| 02 | F | 54 | 26.5 | 6.5 (48) | Tolbutamide 500 + 250 + 250 mg | 1.8 | 2.5 | — | — |
| 03 | M | 27 | 24.3 | 5.4 (36) | Glimepiride 1.5 mg × 1 | 1.8 | 4.0 | — | 1 |
| 04 | M | 38 | 24.4 | 6.5 (48) | Repaglinide 0.5 mg × 2 | 1.8 | 3.0 | — | 1 |
| 05 | M | 24 | 25.1 | 7.0 (53) | No treatment | 1.8 | 1.0 | — | 1 |
| 06† | F | 23 | 25.4 | 4.7 (28) | Glimepiride 0.5 mg × 1 | 1.8 | 1.0 | — | 1 |
| 07‡ | F | 24 | 20.5 | 5.6 (38) | Glimepiride 1.0 mg × 1 | NA | NA | — | — |
| 08 | M | 71 | 26.7 | 6.8 (51) | Gliclazide 30 mg × 1 | 1.8 | 3.0 | — | 1 |
| 09 | F | 25 | 21.3 | 5.4 (36) | Repaglinide 1 mg × 1 | 1.8 | 1.0 | — | 1 |
| 10 | F | 67 | 22.9 | 6.6 (49) | Glimepiride 4.0 mg × 1 | 1.8 | 4.0 | — | — |
| 11† | F | 53 | 26.4 | 6.4 (46) | Glimepiride 1.5 mg × 1 | 1.8 | 3.5 | — | 4 |
| 12 | M | 34 | 27.5 | 7.0 (53) | Glimepiride 1.0 mg × 1 | 1.8 | 3.5 | — | 3 |
| 13 | M | 29 | 26.0 | 5.5 (37) | Glimepiride 1.5 mg × 1 | 1.8 | 1.5 | — | — |
| 14* | F | 56 | 24.5 | 7.9 (63) | Glimepiride 4.0 mg × 1 | 1.8 | 4.0 | — | — |
| 15 | M | 42 | 27.9 | 6.3 (45) | Glimepiride 3.0 mg × 1 | 1.8 | 2.0 | 1 | 3 |
| 16 | M | 28 | 24.4 | 7.3 (56) | Glimepiride 1.0 mg × 1 | 1.8 | 1.0 | — | 2 |
| Mean ± SEM | 39 (range 23–67) | 24.9 ± 0.5 | 6.4 ± 0.2 (47 ± 3) | 1.8 ± 0 | 2.5 ± 0.3 | 1 | 18 | ||
Data are derived from the screening visit (n = 16). F, female; M, male; NA, not applicable.
*†Patients are related (mother and daughter).
‡Patient withdrew from the trial because of intolerable vomiting and diarrhea during the initiation of the first treatment period (liraglutide 0.6 mg, once daily).